Company Overview of Altor BioScience Corporation
Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...
2810 North Commerce Parkway
Miramar, FL 33025-3958
Founded in 2002
Key Executives for Altor BioScience Corporation
Chief Executive Officer, President, and Director
Vice President of Research and Development
Compensation as of Fiscal Year 2015.
Altor BioScience Corporation Key Developments
Altor BioScience Corporation Announces Efficacy and Safety of Alt-801 for Advanced Bladder Cancer at 2015 Asco Annual Meeting
May 28 15
Altor BioScience Corporation announced that it will present updated safety and efficacy data from its ongoing Phase 1b/2 study of ALT-801 in combination with gemcitabine and cisplatin in patients with advanced or metastatic chemo-refractory urothelial cancer. ALT-801 is a novel proprietary immunotherapy composed of IL-2 genetically fused to a soluble T-cell receptor directed against a p53-derived tumor associated antigen. Altor’s approach uses the TCR to guide IL-2 bioactivity to the tumor site, where the cytokine-stimulated immune system attacks the cancerous cells. ALT-801 exhibits a favorable pharmacokinetic and biodistribution profile, improved efficacy and lower toxicity compared to standard IL-2 treatment in various tumor efficacy models. In early phase clinical testing in patients with metastatic malignancies, ALT-801 was well tolerated in the out-patient setting at dose levels that provided treatment-induced immune responses and clinical benefit to patents. Altor has concluded two Phase 1/2 clinical studies of ALT-801 in combination with gemcitabine and cisplatin or gemcitabine alone in patients with advanced/metastatic urothelial cancer. Altor is also conducting a clinical trial of ALT-801 in combination with gemcitabine in patients with Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer.
Altor Bioscience Corporation Appoints Kevin Taylor as Chief Business Officer
Jan 6 15
Altor BioScience Corporation has appointed Mr. Kevin Taylor as its Chief Business Officer. Mr. Taylor will report directly to Hing C. Wong, Ph.D., Chief Executive Officer of Altor. Mr. Taylor brings over 20 years of experience in corporate and business development to the company. He previously was the Chief Business Officer of Nuron Biotech and held business development leadership roles at Cangene Corporation, Adolor Corporation and Codexis. Earlier in his career he held senior positions at Elan Corporation, AstraZeneca and Zeneca Inc.
Altor Bioscience Corporation Initiates Clinical Development of its Novel IL-15 Super Agonist ALT-803 for Relapsed / Refractory Multiple Myeloma
Nov 4 14
Altor BioScience Corporation announced that it has enrolled patients with relapsed or refractory multiple myeloma (MM) in a clinical trial using its IL-15-based immunostimulatory complex ALT-803. This study is supported by a Small Business Innovation Research (SBIR) Phase II grant recently awarded to Altor by the National Cancer Institute (NCI). The MM trial represents the fourth clinical trial in the United States (U.S.) launched by Altor for the ALT-803 superagonist complex in the fight against cancer. As the second most common blood cancer, MM is a cancer of the plasma cells involved in producing antibodies, causing cancer cells to accumulate in the bone marrow and crowding out normal blood cells from fighting off infection. ALT-803 is considered one of the most promising novel immunotherapeutic agents by NCI for cancer treatment. In preclinical studies, ALT-803 potently activates immune cells to defend against disease, simultaneously mobilizing both the innate and adaptive arms of the immune system to elicit rapid and long-lasting anti-tumor responses. Encouraging preclinical studies of ALT-803 in MM led to the development of the ALT-803 clinical study in patients with relapsed or refractory MM. According to NCI, there will be an estimated 24,050 new cases of MM and 11,090 deaths due to MM in the U.S. in 2014. MM is a disease of the elderly with a median age at diagnosis of 69 years. The number of MM patients is expected to increase over time due to the increasing life expectancy of the normal population. Unfortunately, even with the development of novel therapies recently approved by the U.S. Food and Drug Administration (FDA), MM remains an incurable disease and many patients with the disease will eventually relapse. Therefore, Altor's strategy for ALT-803 is to fulfill the needs of this segment of the market and complement or improve the efficacy of currently available therapies.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 20, 2014